Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Sarcojoint®, supervised exercise.
- Who it may be relevant to
- Registry conditions: Sarcopenia, COPD, ILD. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Taiwan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluate the Effect of Dietary Supplement Combined Supervised Exercise on Physical Performance and Body Composition Among Patients With Sarcopenia and Severe Sarcopenia Comorbid With COPD or ILD: A Prospective, Multi-center Cohort Study
Overview
This trial is a prospective multi-center study. The purpose of this study is to evaluate the effect of dietary supplement combined with supervised exercised on the physical performance, body composition and lung function among patients with Sarcopenia and severe Sarcopenia in chronic lung disease. After participants enroll in this study, 12-week clinical trial will be conducted to analyze the improvement regarding Sarcopenia and different severity of Sarcopenia before and after the intervention of exercise and nutritional products, which can further provide reference for clinical intervention and rehabilitation.
Detailed description
The design of clinical trial
This study is a prospective, multi-center, and non-invasive cohort study. All participants are diagnosed with COPD or ILD with Sarcopenia or severe Sarcopenia. The intervention consisted of providing nutritional supplements and supervised exercise for 12 weeks. After the intervention (the 12th week), the trial commissioned company provides nutritional supplements with a market price of about NT$4,000 per month for three months free to participants who are willing to continue taking the products. Those participants will be tracked for one year. The primary purpose of the study is to investigate improvement of physical performance, body composition and lung function before and after the intervention. The secondary purpose of the study is to compare the effect of the same intervention on Sarcopenia and different severity of Sarcopenia regarding the improvement of physical performance, body composition and lung function. Furthermore, the subgroup analysis is conducted to compare those who achieve the exercise requirement with those who do not concerning their physical performance, body composition and lung function.
Trail procedures
1. Baseline demographic characteristic, health behavior and exercise habits are collected by questionnaires. 2. The main disease diagnosis, medication, clinical assessment questionnaire or biochemical examination and radiological examination results are collected. 3. According to the 2019 Asian Sarcopenia Consensus, participants are examined by SARC-Calf questionnaire, grip strength test and a physical performance test, including sit-stand test, short physical performance battery (SPPB), gait speed test and six-minute walk test. Afterward, bioelectrical impedance analysis (BIA) and Dual-energy X-ray absorptiometry (DXA) are applied to all participants to analyze body composition. Participants are classified into Sarcopenia group and severe Sarcopenia group. 4. All patients receive pulmonary function test and blood test ( complete blood count, hepatic function, including \[CHOL、TG、UA、SGOT、SGPT、ALK、BIL、TOTAL.BIL、DIRECT、LDH\], renal function \[BUN、CREAT、CA、CL、NA、K、T、P、ALB\], Albumin, Vitamin D before and after the trail. 5. All participants are administered Sarcojoint® containing leucinine 1 g, arginine 1.5 g, Vitamin D 7.5μg, chondroitin 400 mg, calcium 300 mg, and glucosamine 700 mg per package, and take 1 package twice a day. 6. All participants are required to walk 6500 steps every day for 12 weeks, and the data are recorded by Xiaomi-smart-band. 7. The research nurse provides health education and a recording handbook for exercise and dietary record to participants before the intervention. During the intervention, the research nurse tracks participants' compliance and records the adverse reaction by telephone interview at the first week, and every other week. 8. At the 12th week, all participants receive a comprehensive functional assessment as that at baseline after intervention to investigate the intervention effect on different severity of Sarcopenia. 9. At the 12th week, trial commissioned manufacturer provide nutritional supplements free for 3 months. Those patients will be continuously tracked for the follow-up data for the post hoc analysis.
Interventions
- Dietary supplement Sarcojoint®
All participants are administered Sarcojoint® containing leucinine 1 g, arginine 1.5 g, Vitamin D 7.5μg, chondroitin 400 mg, calcium 300 mg, and glucosamine 700 mg per package, and take 1 package twice a day. - Behavioral supervised exercise
All participants are required to walk 6500 steps every day for 12 weeks, and the data are recorded by Xiaomi-smart-band.
Primary outcome measures
- Change of physical performance (Grip strength) [Time frame: 12 weeks]
- Change of physical performance(Sit to stand test) :SpO2%, HR, Borg score, times and second will be reported to present the result of Sit to stand test. [Time frame: 12 weeks]
- Change of physical performance (SPPB): Sit to stand test, balance test and 4-meter walk test will be combined to report SPPB score [Time frame: 12 weeks]
- Change of physical performance :6-meter walk test (second) [Time frame: 12 weeks]
- Change of physical performance :6-miniute walk test ( SpO2%, HR, Borg score, and the walking distance will be reported to present the result of 6-miniute walk test. ) [Time frame: 12 weeks]
- Change of body composition: BMI(kg/m^2) [Time frame: 12 weeks]
- Change of body composition: SMI (kg/m^2) [Time frame: 12 weeks]
- PBF (%) [Time frame: 12 weeks]
- ASM (kg) [Time frame: 12 weeks]
- LMM (kg) [Time frame: 12 weeks]
Secondary outcome measures (12)
- SARC-Calf questionnaire [Time frame: 12 weeks]
- Grip strength test [Time frame: 12 weeks]
- Sit-stand test [Time frame: 12 weeks]
- Short physical performance battery (SPPB) [Time frame: 12 weeks]
- Gait speed test [Time frame: 12 weeks]
- Six-minute walk test. [Time frame: 12 weeks]
- Bioelectrical impedance analysis (BIA) [Time frame: 12 weeks]
- SMI (kg/m^2) [Time frame: 12 weeks]
- Forced Expiratory Volume in 1 second (FEV1) [Time frame: 12 weeks]
- Forced Expiratory Volume in 1 second as a percentage of predicted value (FEV1 (%)) [Time frame: 12 weeks]
- ratio of Forced Expiratory Volume in 1 second to Forced Vital Capacity as a percentage (FEV1/FVC (%)) [Time frame: 12 weeks]
- Peak Expiratory Flow (PEF (L/min)) [Time frame: 12 weeks]
Eligibility criteria
Inclusion criteria
- Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from Department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment.
- Outpatients who meet the diagnostic criteria for Sarcopenia after evaluation by a physician.
Exclusion criteria
- Patients who refuse to sign the consent form
- Patients who are under 20 years old
- Patients who are bedridden or unable to walk due to physical disabilities
- Patients with terminal cancer or human-acquired immunodeficiency syndrome
- Patients with edema (grading pitting edema +2)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Supportive care
Study locations
Taiwan · 1 center
- Taichung Veterans General Hospital — Taichung
Identifiers
NCT: NCT05926713 · OEP-Sarcojoint